ReviewComparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania — A systematic review and meta-analysis
Introduction
Acute mania is a disorder characterized by an abnormal elevation of mood along with impaired judgment, and disinhibition (American Psychiatric Association, 1994). In general urgent pharmacological management is required to normalize mood, along with hospitalization, as patients are at risk of behaviour that may harm themselves or others (Belmaker, 2004). A number of pharmacological interventions have been shown to be effective in acute mania, including mood stabilizers (MS) such as sodium valproate, lithium and carbamazepine, and both first and second generation antipsychotics (SGAs), as well as combinations of SGA and MS (Fountoulakis and Vieta, 2008). Monotherapy with SGAs or MS are both recommended for acute mania in all recent treatment guidelines (Goodwin, 2009, Yatham et al., 2009, Grunze et al., 2009, Scottish Intercollegiate Guidelines Network, 2005, Suppes et al., 2005, National Institute for Health Clinical Excellence, 2006, American Psychiatric Association, 2002, Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder, 2004), although the process for deriving these guidelines has been criticized (Fountoulakis et al., 2005). Comparing the relative efficacy of these drug classes has been limited by a paucity of head-to-head studies. Whereas monotherapy with SGAs or MS is clearly more efficacious than placebo (Scherk et al., 2007, Perlis et al., 2006, Smith et al., 2007), comparison of monotherapy with MS vs SGA reported similar effect sizes for responder rates (Smith et al., 2007). Another analysis of studies which directly compared MS and SGA monotherapy reported no statistically significant difference between these classes (Scherk et al., 2007). Since these analyses, additional large comparative studies of MS vs SGAs have been completed. The objective of this structured review and meta-analysis was to re-evaluate the comparative efficacy and acceptability of MS and SGA monotherapy in acute mania.
Section snippets
Methods
In this meta-analysis we aimed to identify all drug treatment trials comparing MS and SGA as monotherapy in DSM-IV (American Psychiatric Association, 1994) acute mixed or manic episodes. We selected only those studies that were double blinded, and used randomized allocation to study treatment arms. Studies between 1/1/1950 and 1/12/2009 were included. We attempted to include both published and unpublished studies, through electronic database searches, searches of clinical and pharmaceutical
Results
Fig. 1 summarizes the study selection process. The initial search strategy resulted in 5424 references. This was reduced to 135 studies, on the basis of the title and abstract review. These 135 papers were retrieved and examined. Of these 135 papers a further 126 were excluded, resulting in 9 papers being included in the analysis. The main reasons for exclusion included presentation of duplicate data, and comparison of MS or SGA against placebo or combination therapy (Fig. 1).
Nine studies were
Discussion
This systematic review and meta-analysis has identified that in acute mania, monotherapy with SGAs provides modest but statistically significant advantages over the mood stabilizers valproate and lithium, both in terms of efficacy (greater decrease in mania rating scores score and increased responder rate) and acceptability (lower dropout rate). This effect appears to be independent of type of mood stabilizer. To put the SMD from the present analysis (− 0.22) into a clinical context, this would
Role of the funding source
All authors are employees of the University of Otago. There was no external funding for this analysis.
Conflicts of interest
Professor Herbison and Mr Tarr have no conflicts of interest to report. Professor Glue was employed by Pfizer until 2008.
References (34)
Clinical correlates of therapeutic response in bipolar disorder
J. Affect. Disord.
(2001)- et al.
Treatment guidelines for bipolar disorder: a critical review
J. Affect. Disord.
(2005) - et al.
Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study
J. Affect. Disord.
(2009) - et al.
Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study
Curr. Med. Res. Opin.
(2008) - et al.
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial
J. Affect. Disord.
(2008) Diagnostic and statistical manual of mental disorders
(1994)Practice guideline for the treatment of patients with bipolar disorder
(2002)- et al.
The Bech-Rafaelsen mania scale and the Hamilton depression scale
Acta Psychiatr. Scand.
(1979) Bipolar disorder
N. Engl. J. Med.
(2004)- et al.
Olanzapine compared to lithium in mania: a double-blind randomized controlled trial
Int. Clin. Psychopharmacol.
(1999)
A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder
J. Clin. Psychiatry
Analysing data and undertaking meta-analyses
A diagnostic interview: the schedule for affective disorders and schizophrenia
Arch. Gen. Psychiatry
Treatment of bipolar disorder: a systematic review of available data and clinical perspectives
Int. J. Neuropsychopharmacol.
Evidence-based guidelines for treating bipolar disorder: revised second edition — recommendations from the British Association of Psychopharmacology
J. Psychopharmacol.
The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania
World J. Biol. Psychiatry
Risperidone in the treatment of acute mania: double-blind, placebo-controlled study
Br. J. Psychiatry
Cited by (30)
Can lithium salts prevent depressive episodes in the real world?
2018, European NeuropsychopharmacologyCitation Excerpt :Lithium salts continue to be the first-line treatment for most patients with BD, despite the need for this treatment to be managed by experts given certain features of its use in clinical practice (the need to use sometimes high doses and to monitor plasma levels, and its adverse event profile). Their efficacy to treat acute episodes and to prevent manic/hypomanic relapses has been well documented (Cipriani et al., 2011; Geddes et al., 2004; Tarr et al., 2011). Lithium might be helpful as well in patients with depressive polarity, who are more difficult to treat and have more relapses (González-Pinto et al., 2011).
Olanzapine and aripiprazole differentially affect glucose uptake and energy metabolism in human mononuclear blood cells
2017, Journal of Psychiatric ResearchCitation Excerpt :According to current guidelines, antipsychotics are first line drugs for the treatment of schizophrenia (Baandrup et al., 2016; Lehman et al., 2004). Additionally, antipsychotics are increasingly used for many other psychiatric disorders such as bipolar mania and psychotic depression, in particular second generation antipsychotics (SGA) (Perlis et al., 2006; Tarr et al., 2011; Zhou et al., 2015). In adolescents and adults, there is a clear link between the use of antipsychotic treatment and weight gain, impaired glucose tolerance, and risk of developing type-2 diabetes mellitus, which differs across drugs (Farwell et al., 2004; Galling et al., 2016; Gianfrancesco et al., 2002; Lambert et al., 2006).
Aggression in bipolar II disorder and its relation to the serotonin transporter
2013, Journal of Affective DisordersCitation Excerpt :In our study, aggression and irritability scores were still high when the patients were in the euthymic state. One possible explanation is that the dose of valproic acid in our study was lower than the doses used in previous clinical studies (Bowden et al., 1994; Tarr et al., 2011). To the best of our knowledge, valpoic acid has no direct pharmacological effect on SERT availability (Owens and Nemeroff, 2003).
Clinical Relevance of Treatments for Acute Bipolar Disorder: Balancing Therapeutic and Adverse Effects
2011, Clinical TherapeuticsCitation Excerpt :FDA-approved bipolar disorder treatments include 4 mood stabilizers (MSs; lithium, divalproex, carbamazepine, and lamotrigine) and 6 second-generation antipsychotics (SGAs; olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, and asenapine). Although MSs may be considered foundational treatments for bipolar disorder, recently, utility of SGAs rather than MSs has been emphasized in acute mania treatment reviews,3–5 and SGAs (quetiapine monotherapy and the olanzapine plus fluoxetine combination) rather than MSs comprise the only FDA-approved treatments for acute bipolar depression.6–11 However, for certain patients, the potential efficacy advantages of SGAs may be more than offset by tolerability disadvantages, such as the risk of sedation and/or somnolence (referred to hereafter as sedation) and weight gain.
Bipolar disorder: The foundational role of mood stabilizers
2023, Current PsychiatryClinical psychopathology during COVID-19 pandemic: Case reports of first psychiatric presentations
2021, Psychiatria Danubina